BioCentury
ARTICLE | Company News

AstraZeneca continues to divest Zurampic rights

June 3, 2016 12:53 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it granted Gruenenthal Group (Aachen, Germany) exclusive rights to gout drug Zurampic lesinurad in Europe and Latin America. AZ is eligible for $230 million in sales and other milestones, plus tiered royalties up to the low double digits.

The European Commission approved Zurampic in February for use in combination with a xanthine oxidase inhibitor (XOI) to treat hyperuricemia in adults with gout (see BioCentury Extra, Feb. 19). ...